Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin NPH
Drug: insulin detemir
Drug: insulin aspart

First Posted Date: 2012-10-02

Last Posted Date: 2017-01-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 131

Registration Number: NCT01697657

Locations: 🇸🇪
Novo Nordisk Investigational Site, Trelleborg, Sweden

An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes
Diabetes Mellitus, Type 2

Interventions: Other: No treatment given

First Posted Date: 2012-09-28

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 29304

Registration Number: NCT01696266

Locations: 🇸🇪
Novo Nordisk Investigational Site, Malmö, Sweden

Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A

Phase 1

Completed

Conditions: Congenital Bleeding Disorder
Haemophilia A

Interventions: Drug: turoctocog alfa

First Posted Date: 2012-09-26

Last Posted Date: 2017-02-10

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 15

Registration Number: NCT01692925

Locations: 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain

Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy
Diabetes

Interventions: Drug: NNC0113-0987
Drug: placebo

First Posted Date: 2012-09-21

Last Posted Date: 2017-02-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 45

Registration Number: NCT01690169

Locations: 🇬🇧
Novo Nordisk Investigational Site, Nottingham, United Kingdom

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

Phase 1

Terminated

Conditions: Inflammation
Systemic Lupus Erythematosus

Interventions: Drug: placebo
Drug: NNC0114-0006

First Posted Date: 2012-09-20

Last Posted Date: 2014-04-08

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 10

Registration Number: NCT01689025

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Houston, Texas, United States

Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2
Healthy
Diabetes

Interventions: Drug: semaglutide
Drug: placebo

First Posted Date: 2012-09-18

Last Posted Date: 2019-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 107

Registration Number: NCT01686945

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2012-09-11

Last Posted Date: 2017-01-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT01682902

Locations: 🇺🇸
Novo Nordisk Investigational Site, Atlanta, Georgia, United States

Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Delivery Systems

Interventions: Other: 19 injections
Drug: sodium chloride 0.9% solution

First Posted Date: 2012-09-07

Last Posted Date: 2017-03-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 82

Registration Number: NCT01680328

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2012-09-07

Last Posted Date: 2018-04-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 272

Registration Number: NCT01680341

Locations: 🇹🇷
Novo Nordisk Investigational Site, Istanbul, Turkey

The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin degludec/liraglutide
Drug: liraglutide
Drug: exenatide

First Posted Date: 2012-08-30

Last Posted Date: 2019-01-03

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 438

Registration Number: NCT01676116

Locations: 🇸🇰
Novo Nordisk Investigational Site, Presov, Slovakia

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy